SAB Biotherapeutics (SABS) Non-Current Debt (2020 - 2022)
SAB Biotherapeutics' (SABS) quarterly Non-Current Debt came in at $541644.0 in Q4 2022, up 214.84% on a QoQ basis from $172037.0 in Q4 2020.
Powered by 
Analysis
SAB Biotherapeutics (SABS) Non-Current Debt (2020 - 2022) Analysis & Trends
SAB Biotherapeutics (SABS) has 2 years of Non-Current Debt data on file, last reported at $541644.0 in Q4 2022.
- Quarterly Non-Current Debt changed N/A year-over-year to $541644.0 in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $541644.0 (changed N/A YoY) and the FY2022 annual result came in at $541644.0, changed N/A from the prior year.
- Non-Current Debt rose to $541644.0 in Q4 2022, from $172037.0 in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $541644.0 in Q4 2022 to a low of $172037.0 in Q4 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 591.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 882.16 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 8.96 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 546.77 Mn |
| 10 | SAB Biotherapeutics | 296.68 Mn | 296.68 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2022 | 541,644.00 |
| Dec 31, 2021 | 1.80 Mn |
| Dec 31, 2020 | 710,768.00 |